Stock Analysis on Net
Stock Analysis on Net

Humana Inc. (NYSE:HUM)

This company has been moved to the archive! The financial data has not been updated since October 30, 2024.

Analysis of Profitability Ratios

Microsoft Excel

Profitability Ratios (Summary)

Return on Sales

Return on Investment

Humana Inc., profitability ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Return on Sales
Operating profit margin 3.81% 4.11% 3.80% 6.56% 4.96%
Net profit margin 2.36% 3.03% 3.54% 4.43% 4.20%
Return on Investment
Return on equity (ROE) 15.31% 18.33% 18.24% 24.53% 22.49%
Return on assets (ROA) 5.29% 6.52% 6.61% 9.63% 9.31%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


An analysis of profitability metrics between 2019 and 2023 reveals a general downward trend in efficiency and earnings capacity following a peak in 2020. While the company experienced a temporary increase in profitability across all ratios during 2020, subsequent years have been characterized by a steady contraction in margins and returns on invested capital.

Profit Margin Analysis
The operating profit margin peaked at 6.56% in 2020 before experiencing a sharp decline to 3.80% in 2021. Although a slight recovery to 4.11% occurred in 2022, the margin returned to 3.81% by 2023, indicating a stabilization at a lower threshold compared to 2019 levels. In contrast, the net profit margin has exhibited a more consistent and linear decline since 2020, falling from 4.43% to 2.36% by the end of 2023. The divergence between the stabilizing operating margin and the falling net margin suggests that non-operating expenses or tax burdens have placed increasing pressure on the final bottom line.
Return on Equity (ROE)
ROE demonstrated significant volatility, reaching a high of 24.53% in 2020. A substantial contraction occurred in 2021, with the ratio dropping to 18.24%. Following a period of relative stability in 2022, ROE declined further to 15.31% in 2023. This overall trajectory indicates a reduced ability to generate profit from shareholders' equity over the five-year period.
Return on Assets (ROA)
The ROA trend mirrors the pattern observed in ROE, peaking at 9.63% in 2020 before entering a sustained decline. The ratio fell to 6.61% in 2021 and continued to erode, reaching 5.29% by December 31, 2023. This downward movement suggests a decrease in asset utilization efficiency and a reduction in the profitability generated per unit of total assets.

In summary, the data indicates a period of peak profitability in 2020 followed by a multi-year decline. The simultaneous contraction of ROE, ROA, and net profit margins suggests a systemic reduction in overall financial performance and efficiency throughout the observed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Operating Profit Margin

Humana Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Income from operations 4,013 3,800 3,148 4,986 3,192
External revenues 105,305 92,488 82,877 76,001 64,387
Profitability Ratio
Operating profit margin1 3.81% 4.11% 3.80% 6.56% 4.96%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 16.15% 19.16% 19.56% — —
Elevance Health Inc. 4.47% 4.94% 5.15% — —
Intuitive Surgical Inc. 24.80% 25.35% 31.89% — —
Medtronic PLC 17.56% 18.15% 14.89% — —
UnitedHealth Group Inc. 8.80% 8.83% 8.40% — —
Operating Profit Margin, Sector
Health Care Equipment & Services 8.71% 9.26% 9.13% — —
Operating Profit Margin, Industry
Health Care 12.79% 18.74% 18.04% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Operating profit margin = 100 × Income from operations ÷ External revenues
= 100 × 4,013 ÷ 105,305 = 3.81%

2 Click competitor name to see calculations.


An analysis of the financial performance from 2019 to 2023 reveals a period of consistent top-line growth contrasted by volatility in operational efficiency. While external revenues expanded steadily throughout the five-year period, operating income and the resulting profit margins experienced significant fluctuations, indicating that revenue growth did not translate linearly into operational profit.

External Revenue Growth
A sustained upward trajectory in external revenues is observed, increasing from US$ 64,387 million in 2019 to US$ 105,305 million by December 31, 2023. This represents a consistent year-over-year expansion, reflecting a significant increase in the scale of business operations.
Operating Income Volatility
Income from operations exhibited non-linear movement. A peak occurred in 2020 at US$ 4,986 million, followed by a sharp contraction to US$ 3,148 million in 2021. A gradual recovery followed, with operating income rising to US$ 3,800 million in 2022 and reaching US$ 4,013 million in 2023. Despite the recovery, the 2023 figures remain below the 2020 peak despite substantially higher revenues.
Operating Profit Margin Trends
The operating profit margin reflects the underlying volatility in cost management relative to revenue. The margin peaked at 6.56% in 2020, coinciding with the highest operating income. However, a significant compression occurred in 2021, where the margin dropped to 3.80%. Although a slight improvement to 4.11% was noted in 2022, the margin returned to 3.81% in 2023. This suggests that the cost of generating revenue increased disproportionately during the latter part of the period, leading to a compression of the operational margin compared to 2019 and 2020 levels.

In summary, the trend indicates a divergence between revenue scaling and operational profitability. The ability to maintain the higher margins seen in 2020 was not sustained, and the organization has operated at a lower margin threshold of approximately 3.8% to 4.1% since 2021, despite a larger revenue base.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Net Profit Margin

Humana Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Net income attributable to Humana 2,489 2,806 2,933 3,367 2,707
External revenues 105,305 92,488 82,877 76,001 64,387
Profitability Ratio
Net profit margin1 2.36% 3.03% 3.54% 4.43% 4.20%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 14.27% 15.88% 16.42% — —
Elevance Health Inc. 3.52% 3.87% 4.46% — —
Intuitive Surgical Inc. 25.24% 21.25% 29.85% — —
Medtronic PLC 12.03% 15.90% 11.97% — —
UnitedHealth Group Inc. 6.09% 6.25% 6.06% — —
Net Profit Margin, Sector
Health Care Equipment & Services 6.43% 7.05% 7.14% — —
Net Profit Margin, Industry
Health Care 11.49% 14.65% 15.24% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Net profit margin = 100 × Net income attributable to Humana ÷ External revenues
= 100 × 2,489 ÷ 105,305 = 2.36%

2 Click competitor name to see calculations.


A divergence is observed between revenue growth and bottom-line profitability from 2019 to 2023. While external revenues expanded consistently throughout the period, net income peaked in 2020 and subsequently declined, leading to a sustained compression of the net profit margin.

External Revenue Trend
External revenues demonstrated uninterrupted growth, increasing from 64,387 million USD in 2019 to 105,305 million USD in 2023. This reflects a consistent upward trajectory in top-line scale.
Net Income Performance
Net income attributable to the company rose to a peak of 3,367 million USD in 2020 but experienced a steady decrease over the subsequent three years, falling to 2,489 million USD by December 31, 2023.
Net Profit Margin Analysis
The net profit margin followed a pattern of initial growth followed by steady erosion. After reaching a high of 4.43% in 2020, the margin declined to 3.54% in 2021, 3.03% in 2022, and finally to 2.36% in 2023. This trend indicates that the growth in external revenues was offset by a more rapid increase in operating costs or other expenses, thereby reducing the overall efficiency of converting revenue into net profit.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Return on Equity (ROE)

Humana Inc., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Net income attributable to Humana 2,489 2,806 2,933 3,367 2,707
Stockholders’ equity 16,262 15,311 16,080 13,728 12,037
Profitability Ratio
ROE1 15.31% 18.33% 18.24% 24.53% 22.49%
Benchmarks
ROE, Competitors2
Abbott Laboratories 14.83% 18.90% 19.75% — —
Elevance Health Inc. 15.23% 16.59% 16.93% — —
Intuitive Surgical Inc. 13.51% 11.98% 14.32% — —
Medtronic PLC 7.30% 9.59% 7.01% — —
UnitedHealth Group Inc. 25.22% 25.87% 24.09% — —
ROE, Sector
Health Care Equipment & Services 17.13% 18.40% 17.28% — —
ROE, Industry
Health Care 19.40% 24.82% 25.44% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
ROE = 100 × Net income attributable to Humana ÷ Stockholders’ equity
= 100 × 2,489 ÷ 16,262 = 15.31%

2 Click competitor name to see calculations.


The financial trajectory from 2019 to 2023 indicates a compression in profitability relative to shareholders' equity. While the Return on Equity (ROE) reached a peak in 2020, a subsequent downward trend is observed, with the ratio declining to 15.31% by the end of 2023.

Net Income Performance
Net income attributable to the company peaked in 2020 at US$ 3,367 million. Following this peak, a consistent year-over-year decline was recorded, with net income falling to US$ 2,933 million in 2021, US$ 2,806 million in 2022, and reaching a period low of US$ 2,489 million in 2023.
Equity Base Expansion
Stockholders' equity exhibited a general growth pattern, increasing from US$ 12,037 million in 2019 to US$ 16,262 million in 2023. Despite a marginal decrease in 2022, the overall expansion of the equity base contributed to the dilution of the return ratio over the five-year period.
ROE Analysis
The decline in ROE is attributable to the simultaneous occurrence of falling net income and a rising equity base. The most pronounced contraction occurred between 2020 and 2021, where ROE dropped from 24.53% to 18.24%. Although the ratio remained stable in 2022 at 18.33%, it continued to erode in 2023, reflecting a diminished efficiency in generating profit from the available shareholder capital.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Return on Assets (ROA)

Humana Inc., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Net income attributable to Humana 2,489 2,806 2,933 3,367 2,707
Total assets 47,065 43,055 44,358 34,969 29,074
Profitability Ratio
ROA1 5.29% 6.52% 6.61% 9.63% 9.31%
Benchmarks
ROA, Competitors2
Abbott Laboratories 7.82% 9.31% 9.40% — —
Elevance Health Inc. 5.50% 5.86% 6.26% — —
Intuitive Surgical Inc. 11.64% 10.19% 12.58% — —
Medtronic PLC 4.13% 5.54% 3.87% — —
UnitedHealth Group Inc. 8.18% 8.19% 8.15% — —
ROA, Sector
Health Care Equipment & Services 7.05% 7.49% 7.28% — —
ROA, Industry
Health Care 7.19% 9.66% 9.46% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
ROA = 100 × Net income attributable to Humana ÷ Total assets
= 100 × 2,489 ÷ 47,065 = 5.29%

2 Click competitor name to see calculations.


An analysis of the financial metrics from 2019 through 2023 reveals a significant decline in asset utilization efficiency. Although the organization experienced substantial asset growth, this expansion was not matched by corresponding increases in net income, resulting in a persistent downward trajectory for the return on assets (ROA).

Net Income Trends
Net income attributable to the company peaked in 2020 at US$ 3,367 million, following an initial increase from US$ 2,707 million in 2019. However, a steady decline occurred over the subsequent three years, with earnings decreasing to US$ 2,489 million by the end of 2023.
Asset Base Expansion
Total assets exhibited a strong upward trend, growing from US$ 29,074 million in 2019 to US$ 47,065 million in 2023. Aside from a slight contraction in 2022, the asset base expanded by approximately 62% over the five-year period.
Return on Assets (ROA) Interpretation
The ROA reached a maximum of 9.63% in 2020 before experiencing a sharp decline to 6.61% in 2021. This deterioration continued through 2023, closing at 5.29%. The compression of the ROA is a direct result of the divergence between shrinking net income and an expanding asset base, indicating a reduction in the company's ability to generate profit from its investments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?